Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Frost Factor: An M&A Leader's Standout Strategy For Opko Health

Feb 22 2017

• By William Looney

Frost_Phillip_1200x675

Related Content

US FDA’s First Complete Response Letter Of 2017 Involves … Manufacturing

Jan 13 2017

Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics

Aug 01 2005

Opko Embarks On Transition To Profitability With Discount Buy

Jun 30 2016

Frost On The Art Of The Deal

Feb 22 2017

Frost On Opportunities In Quality-Of-Life Therapies

Feb 22 2017

Another Pfizer deal: Opko's once-weekly growth hormone

Dec 16 2014

OPKO bags US’ No 3 clinical lab operator for $1.47bn

Jun 05 2015

Related Companies

Opko Health

CSL Vifor

Key Pharmaceuticals Inc.

Schering-Plough

Ivax Corp.

Teva Pharmaceutical Industries Ltd.

Tesaro, Inc.

Transition Therapeutics Inc.

Opko Health

Pfizer Inc.

Additional Topics

Business Strategies Deals Leadership BioPharmaceutical

More from Business Strategy

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window